 MELBOURNE, Australia, Oct. 26, 2022 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore. 